Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,782

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Sever, Peter S, Dahlöf, Björn, Poulter, Neil R, Wedel, Hans, Beevers, Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Östergren, Jan·2003·The Lancet
DOI 10.1016/s0140-6736(03)12948-0
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)12948-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 19

  1. 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
  2. Athyros, 2002, The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787 · DOI · Paper page
  3. Serruys, 2002, Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomised controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215 · DOI · Paper page
  4. 2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care, JAMA, 288, 2998, 10.1001/jama.288.23.2998 · DOI · Paper page
  5. Stamler, 1986, Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?, JAMA, 256, 2823, 10.1001/jama.1986.03380200061022 · DOI · Paper page
  6. 1998, Blood pressure, cholesterol, and stroke in eastern Asia, Lancet, 352, 1801, 10.1016/S0140-6736(98)03454-0 · DOI · Paper page
  7. Crouse, 1998, HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data, Atherosclerosis, 138, 11, 10.1016/S0021-9150(98)00014-8 · DOI
  8. Martin, 1986, Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men, Lancet, 2, 933, 10.1016/S0140-6736(86)90597-0 · DOI · Paper page
  9. Maron, 2000, Current perspectives on statins, Circulation, 18, 207, 10.1161/01.CIR.101.2.207 · DOI · Paper page
  10. Sever, 2001, Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial, J Hypertens, 6, 1139, 10.1097/00004872-200106000-00020 · DOI · Paper page
  11. Hansson, 1992, Prospective Randomised Open Blinded Endpoint (PROBE) study: a novel design for intervention trials, Blood Pressure, 1, 113, 10.3109/08037059209077502 · DOI · Paper page
  12. Freeman, 2001, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, 357, 10.1161/01.CIR.103.3.357 · DOI · Paper page
  13. Bucher, 1999, Systematic review on the risk and benefit of different cholesterol-lowering interventions, Arterioscler Thromb Vasc Biol, 19, 187, 10.1161/01.ATV.19.2.187 · DOI
  14. Ramsay, 1999, Guidelines for management of hypertension: report of the third working party of the British Hypertension Society, 1999, J Hum Hypertens, 13, 569, 10.1038/sj.jhh.1000917 · DOI · Paper page
  15. 1998, Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments, J Hypertens, 16, 127
  16. 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, JAMA, 285, 2487
  17. Ramsay, 1996, Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table, Lancet, 348, 387, 10.1016/S0140-6736(96)05516-X · DOI
  18. Wood, 1998, Joint British recommendations on prevention of coronary heart disease in clinical practice, Heart, 80, S1
  19. Glorioso, 1999, Effect of the MHG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia, Hypertension, 34, 1281, 10.1161/01.HYP.34.6.1281 · DOI · Paper page

Cited by

See all 3,782

Metadata

Authors
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., & Östergren, J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-04
Volume
361
Issue
9364
Pages
1149-1158
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(03)12948-0
OpenAlex
W2031185570
Cited by
3,782
References
10
FWCI
355.37
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(03)12948-0
The paper
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., & Östergren, J. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(03)12948-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.